ClinicalTrials.gg
CompletedNCT02011113Updated Nov 1, 2016Results posted

Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma

A Phase 2 interventional study of Pomalidomide and Dexamethasone in Multiple Myeloma, sponsored by Celgene Corporation. Completed at 14 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2016-11-01.

Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 102 studies testing pomalidomide in Multiple Myeloma — 15 open to participants now, 39 under way, 9 of them phase 3. pomalidomide · Multiple Myeloma.

Enrollment
62nd of 102
36 · median 50
Started
2013
with 3 others
Phase 2
55 of 102
9 open now
Registered
26th of 102
by date
Lead sponsor
2 of 102
Celgene Corporation

Among the 102 studies testing pomalidomide in Multiple Myeloma, this one is the 62nd largest by enrollment, is one of 4 that started in 2013, is one of 55 in phase 2, and was the 26th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 102 studies testing pomalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About pomalidomide

pomalidomide: first FDA approval 2013 (POMALYST), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies testing pomalidomide in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of pomalidomide in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Pomalidomide,
  • CC-4047,
  • Dexamethasone,
  • Relapsed and refractory multiple myeloma,
  • phase 2
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Must be ≥ 20 years of age at the time of signing the document.

      1. The subject must understand and voluntarily sign an informed consent document before any study related assessments/procedures are conducted.
      1. Must be able to adhere to the study visit schedule and other protocol requirements.
      1. Have a documented diagnosis of multiple myeloma and have disease. Subjects must have received at least 2 prior therapies. Subjects must have relapsed after having achieved at least stable disease for at least one cycle of treatment to at least one prior regimen and then developed progressive disease(PD). Subjects must also have documented evidence of progressive disease(PD) during or within 60 days (measured from the end of the last cycle) of completing treatment with the last antimyeloma drug regimen used just prior to study entry (refractory disease).
      1. Subjects must have undergone prior treatment with at least 2 cycles of lenalidomide and at least 2 cycles of bortezomib (either in separate regimens or within the same regimen).
      1. Subjects must have documented diagnosis of multiple myeloma and have (serum M-protein ≥ 0.5 g/dL or urine M-protein ≥ 200 mg/24 hours).
      1. (ECOG) performance status score of 0, 1, or 2.

      8.Must agree to comply to pomalidomide Pregnancy Prevention Risk Management Plan.

Exclusion criteria

Exclusion Criteria:

    1. Pregnant or breastfeeding females 2. to thalidomide, lenalidomide, or dexamethasone 3. ≥ Grade 3 rash during prior thalidomide or lenalidomide therapy 4. Subjects unable or unwilling to undergo antithrombotic prophylactic treatment will not be eligible to participate in this study 5. Any of the following laboratory abnormalities:

      • \< 1,000/µL
      • count \< 75,000/µL for subjects in whom \< 50% of bone marrow nucleated cells are plasma cells; or a platelet count \< 30,000/µL for subjects in whom ≥ 50% of bone marrow nucleated cells are plasma cells
      • \< 45 mL/min according to Cockcroft-Gault formula

Cockcroft-Gault estimation of Creatinine Clearance:

  • Corrected serum calcium > 14 mg/dL (> 3.5 mmol/L)
  • \< 8 g/dL (\< 4.9 mmol/L; prior Red blood cell transfusion or recombinant human erythropoietin use is permitted)
  • Serum glutamic oxaloacetic transaminase()/aspartate aminitransferase(AST) or serum glutamic pyruvic transaminase(SGPT)/alanine aminotransferase(ALT) > 3.0 x (ULN)
  • Serum total > 2.0 mg/dL (34.2 μmol/L); or ≥ 3.0 x upper limit of normal (ULN) for subjects with hereditary benign hyperbilirubinemia.

    1. Subjects with any one of the following:
  • Congestive heart failure ( Class III or IV)
  • Myocardial infarction within 12 months prior to starting study treatment
  • Unstable or poorly controlled angina pectoris, including Prinzmetal variant angina pectoris 7. Peripheral neuropathy ≥ Grade 2. 8. Prior history of , other than multiple myeloma, unless the subject has been free of the disease for ≥ 5 years. Exceptions include the following:
  • Basal or Squamous cell carcinoma of the skin
  • Carcinoma in situ of the cervix or breast
  • Incidental histologic finding of prostate cancer (TNM stage of T1a or T1b) 9. Known infection with (HIV) antibody positive, virus surface antigen (HBsAg) positive or virus antibody (HCVAb) positive. If negative for hepatitis B virus surface antigen (HBsAg) but hepatitis B core antibody (HBcAb) and/or hepatitis B surface antibody (HBsAb) positive status, a hepatitis B virus DNA test will be performed and if positive the subject will be excluded.

    1. Incidence of gastrointestinal disease that may significantly alter the absorption of pomalidomide.
    1. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
    1. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
    1. Any condition that confounds the ability to interpret data from the study. 14. Previous therapy with pomalidomide. 15. Use of any agents within 28 days or 5 half-lives (whichever is longer) of treatment.
    1. Subjects with conditions requiring chronic or treatment, such as rheumatoid arthritis, multiple sclerosis, and lupus, which likely need additional steroid or immunosuppressive treatments in addition to the study treatment. Includes subjects receiving corticosteroids (> 10 mg/day of prednisone or equivalent) within 3 weeks prior to enrollment.
    1. Subjects who received any of the following within the last 14 days of initiation of study treatment:
  • Plasmapheresis
  • Major surgery (kyphoplasty is not considered major surgery)
  • Radiation therapy
  • Use of any antimyeloma drug therapy. 18. Subjects who received an allogeneic bone marrow or peripheral blood stem cell transplant less than 12 months prior to initiation of study treatment and who have not discontinued immunosuppressive treatment for at least 4 weeks prior to initiation of study treatment and are currently dependent on such treatment.

    1. Subjects who are planning for or who are eligible for stem cell transplant.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Pomalidomide plus dexamethasone

    Drug: Pomalidomide · Drug: Dexamethasone

Interventions

  • 4 mg oral pomalidomide once daily Days 1-21 of each 28-day cycle

    Also known as: CC-4047

  • 40 mg or 20 mg oral dexamethasone once daily on Days 1, 8, 15, 22 of each 28-day cycle

    Also known as: LenaDex

06

What researchers measure

Primary outcomes

  1. Myeloma Response Rate Based on the International Myeloma Working Group (IMWG) Uniform Response Criteria

    Myeloma response was defined as a best overall response of stringent complete response (SCR), complete response (CR), very good partial response (VGPR) or partial response (PR) SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level \< 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to \< 200 mg/24 hours. In addition to the above, if present at baseline a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required.

    Time frame: From the first dose until the data cut-off date of 03 Sept 2014; Maximum time in follow-up was 36.0 weeks.

  2. Myeloma Response Rate Based on the International Myeloma Working Group (IMWG) Uniform Response Criteria (Later Cut-off Date)

    Myeloma response was defined as a best overall response of stringent complete response (SCR), complete response (CR), very good partial response (VGPR) or partial response (PR) SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level \< 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to \< 200 mg/24 hours. In addition to the above, if present at baseline a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required.

    Time frame: From the first dose until the final data cut-off date of 25 September 2015; maximum duration on treatment was 80.9 weeks

Secondary outcomes

  1. Myeloma Response Rate Based on European Group for Blood and Marrow Transplantation (EBMT) Criteria

    Myeloma response was defined as a best overall response of complete response (CR) or partial response (PR) CR is defined as: - Absence of original monoclonal paraprotein in serum and urine by immunofixation maintained at least 42 days. - \<5% plasma cell in bone marrow aspirate and on bone marrow biopsy, if performed. - No increase in size or number of lytic bone lesions. - Disappearance of soft tissue plasmacytomas. PR requires all of the following: - ≥ 50% reduction in level of serum monoclonal paraprotein, maintained at least 42 days. - Reduction in 24-hour urinary light chain extraction by ≥ 90% or to \< 200 mg, maintained at least 42 days. - For patients with non-secretory myeloma, ≥ 50% reduction in plasma cells in bone marrow aspirate and on biopsy, if performed, for at least 42 days. - ≥ 50% reduction in the size of soft tissue plasmacytomas. - No increase in size or number of lytic bone lesions.

    Time frame: From first dose until the data cut-off date of 03 September 2014; maximum time in follow-up was 36.0 weeks

  2. Time to Response

    Time to response was calculated as the time from the first dose to the initial documented response (partial response or better) based on IMWG criteria. SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level \< 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to \< 200 mg/24 hours. If present at baseline a ≥ 50% reduction in size of soft tissue plasmacytomas is also required.

    Time frame: From the first dose until the data cut-off date of 03 September 2014. Maximum time on follow-up was 36.0 weeks.

  3. Myeloma Response Rate Based on European Group for Blood and Marrow Transplantation (EBMT) Criteria (Later Cut-off Date)

    Myeloma response was defined as a best overall response of complete response (CR) or partial response (PR) CR is defined as: - Absence of original monoclonal paraprotein in serum and urine by immunofixation maintained at least 42 days. - \<5% plasma cell in bone marrow aspirate and on bone marrow biopsy, if performed. - No increase in size or number of lytic bone lesions. - Disappearance of soft tissue plasmacytomas. PR requires all of the following: - ≥ 50% reduction in level of serum monoclonal paraprotein, maintained at least 42 days. - Reduction in 24-hour urinary light chain extraction by ≥ 90% or to \< 200 mg, maintained at least 42 days. - For patients with non-secretory myeloma, ≥ 50% reduction in plasma cells in bone marrow aspirate and on biopsy, if performed, for at least 42 days. - ≥ 50% reduction in the size of soft tissue plasmacytomas. - No increase in size or number of lytic bone lesions.

    Time frame: From the first dose until the final data cut-off date of 25 September 2015; maximum duration on treatment was 80.9 weeks

  4. Time to Response (Later Cut-off Date)

    Time to response was calculated as the time from the first dose to the initial documented response (partial response or better) based on IMWG criteria. SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level \< 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to \< 200 mg/24 hours. If present at baseline a ≥ 50% reduction in size of soft tissue plasmacytomas is also required.

    Time frame: From the first dose until the final data cut-off date of 25 September 2015; maximum duration on treatment was 80.9 weeks

  5. Kaplan-Meier Estimates of Duration of Response

    Duration of response (calculated for responders only) was defined as time from the initial documented response (partial response or better) to confirmed disease progression, based on IMWG criteria.

    Time frame: From first dose until the data cut-off date of 03 September 2014; maximum time for follow-up was 36 weeks

  6. Kaplan-Meier Estimates of Duration of Response (Later Cut-off Date)

    Duration of response (calculated for responders only) was defined as time from the initial documented response (partial response or better) to confirmed disease progression, based on IMWG criteria.

    Time frame: From the first dose until the final data cut-off date of 25 September 2015; maximum duration on treatment was 80.9 weeks

  7. Kaplan-Meier Estimates of Progression-free Survival (PFS)

    PFS was calculated as the time from the first dosing to the first documented progressive disease, as determined by the investigators based on the IMWG Uniform Response criteria, or death, whichever occurred earlier

    Time frame: From the first dose until the data cut-off date of 03 September 2014; maximum time on treatment was 36.0 weeks

  8. Kaplan-Meier Estimates of PFS (Later Cut-off Date)

    PFS was calculated as the time from the first dosing to the first documented progressive disease, as determined by the investigators based on the IMWG Uniform Response criteria, or death, whichever occurred earlier

    Time frame: From the first dose until the final data cut-off date of 25 September 2015; maximum duration on treatment was 80.9 weeks

  9. Number of Participants With Adverse Events

    Relation to study drug was assessed by the Investigator as either suspected or not suspected. Counts represent the suspected relationship. Severity was assessed using National Cancer Institute Common Toxicity Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0): 1= Mild 2= Moderate 3= Severe 4= Life-threatening and 5= Death related to AE. Serious AEs (SAEs) were those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above. Treatment Emergent Adverse Event (TEAE) was defined as any AE occurring on or after the first treatment of the study medication and within 28 days after the last dose.

    Time frame: From first dose of study drug to final data cut-off date of 25 Sept 2015, maximum duration on treatment was 80.9 weeks

07

Results

Posted Nov 10, 2015

Participant flow

All study participants who were on pomalidomide were transferred to the post-marketing study and continued the study treatment when pomalidomide became commercially available.

Participant flow — Overall Study
MilestonePomalidomide Plus Dexamethasone
Started36
Completed0
Not completed36
Withdrew: Adverse event4
Withdrew: Disease progression (dp)16
Withdrew: Death1
Withdrew: Insufficient effect of pomalidomide1
Withdrew: Investigator's judgement- dp3
Withdrew: Study terminated by sponsor11

Outcome measures

PrimaryMyeloma Response Rate Based on the International Myeloma Working Group (IMWG) Uniform Response Criteria

Myeloma response was defined as a best overall response of stringent complete response (SCR), complete response (CR), very good partial response (VGPR) or partial response (PR) SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level \< 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to \< 200 mg/24 hours. In addition to the above, if present at baseline a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required.

Time frame:
From the first dose until the data cut-off date of 03 Sept 2014; Maximum time in follow-up was 36.0 weeks.
Reported as:
Number · percentage of participants responding
Myeloma Response Rate Based on the International Myeloma Working Group (IMWG) Uniform Response Criteria
percentage of participants respondingPomalidomide Plus Dexamethasone
Myeloma Response Rate Based on the International Myeloma Working Group (IMWG) Uniform Response Criteria25.0 (10.855 to 39.145)
Statistical analysis
  • Pomalidomide Plus Dexamethasone · Binomial test for dichotomized response · p = 0.0027 (Based on one sample binomial test for dichotomized response proportion against the null hypothesis(H0: p = 0.1))
SecondaryMyeloma Response Rate Based on European Group for Blood and Marrow Transplantation (EBMT) Criteria

Myeloma response was defined as a best overall response of complete response (CR) or partial response (PR) CR is defined as: - Absence of original monoclonal paraprotein in serum and urine by immunofixation maintained at least 42 days. - \<5% plasma cell in bone marrow aspirate and on bone marrow biopsy, if performed. - No increase in size or number of lytic bone lesions. - Disappearance of soft tissue plasmacytomas. PR requires all of the following: - ≥ 50% reduction in level of serum monoclonal paraprotein, maintained at least 42 days. - Reduction in 24-hour urinary light chain extraction by ≥ 90% or to \< 200 mg, maintained at least 42 days. - For patients with non-secretory myeloma, ≥ 50% reduction in plasma cells in bone marrow aspirate and on biopsy, if performed, for at least 42 days. - ≥ 50% reduction in the size of soft tissue plasmacytomas. - No increase in size or number of lytic bone lesions.

Time frame:
From first dose until the data cut-off date of 03 September 2014; maximum time in follow-up was 36.0 weeks
Reported as:
Number · percentage of participants responding
Myeloma Response Rate Based on European Group for Blood and Marrow Transplantation (EBMT) Criteria
percentage of participants respondingPomalidomide Plus Dexamethasone
Myeloma Response Rate Based on European Group for Blood and Marrow Transplantation (EBMT) Criteria22.2 (8.642 to 35.803)
SecondaryTime to Response

Time to response was calculated as the time from the first dose to the initial documented response (partial response or better) based on IMWG criteria. SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level \< 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to \< 200 mg/24 hours. If present at baseline a ≥ 50% reduction in size of soft tissue plasmacytomas is also required.

Time frame:
From the first dose until the data cut-off date of 03 September 2014. Maximum time on follow-up was 36.0 weeks.
Reported as:
Median · weeks
Time to Response
weeksPomalidomide Plus Dexamethasone
Time to Response4.10 (4.10 to 24.1)
PrimaryMyeloma Response Rate Based on the International Myeloma Working Group (IMWG) Uniform Response Criteria (Later Cut-off Date)

Myeloma response was defined as a best overall response of stringent complete response (SCR), complete response (CR), very good partial response (VGPR) or partial response (PR) SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level \< 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to \< 200 mg/24 hours. In addition to the above, if present at baseline a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required.

Time frame:
From the first dose until the final data cut-off date of 25 September 2015; maximum duration on treatment was 80.9 weeks
Reported as:
Number · percentage of participants responding
Myeloma Response Rate Based on the International Myeloma Working Group (IMWG) Uniform Response Criteria (Later Cut-off Date)
percentage of participants respondingPomalidomide Plus Dexamethasone
Myeloma Response Rate Based on the International Myeloma Working Group (IMWG) Uniform Response Criteria (Later Cut-off Date)41.7 (25.562 to 57.771)
SecondaryMyeloma Response Rate Based on European Group for Blood and Marrow Transplantation (EBMT) Criteria (Later Cut-off Date)

Myeloma response was defined as a best overall response of complete response (CR) or partial response (PR) CR is defined as: - Absence of original monoclonal paraprotein in serum and urine by immunofixation maintained at least 42 days. - \<5% plasma cell in bone marrow aspirate and on bone marrow biopsy, if performed. - No increase in size or number of lytic bone lesions. - Disappearance of soft tissue plasmacytomas. PR requires all of the following: - ≥ 50% reduction in level of serum monoclonal paraprotein, maintained at least 42 days. - Reduction in 24-hour urinary light chain extraction by ≥ 90% or to \< 200 mg, maintained at least 42 days. - For patients with non-secretory myeloma, ≥ 50% reduction in plasma cells in bone marrow aspirate and on biopsy, if performed, for at least 42 days. - ≥ 50% reduction in the size of soft tissue plasmacytomas. - No increase in size or number of lytic bone lesions.

Time frame:
From the first dose until the final data cut-off date of 25 September 2015; maximum duration on treatment was 80.9 weeks
Reported as:
Number · percentage of participants responding
Myeloma Response Rate Based on European Group for Blood and Marrow Transplantation (EBMT) Criteria (Later Cut-off Date)
percentage of participants respondingPomalidomide Plus Dexamethasone
Myeloma Response Rate Based on European Group for Blood and Marrow Transplantation (EBMT) Criteria (Later Cut-off Date)38.9 (22.964 to 54.814)
SecondaryTime to Response (Later Cut-off Date)

Time to response was calculated as the time from the first dose to the initial documented response (partial response or better) based on IMWG criteria. SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level \< 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to \< 200 mg/24 hours. If present at baseline a ≥ 50% reduction in size of soft tissue plasmacytomas is also required.

Time frame:
From the first dose until the final data cut-off date of 25 September 2015; maximum duration on treatment was 80.9 weeks
Reported as:
Median · weeks
Time to Response (Later Cut-off Date)
weeksPomalidomide Plus Dexamethasone
Time to Response (Later Cut-off Date)8.10 (4.1 to 24.1)
SecondaryKaplan-Meier Estimates of Duration of Response

Duration of response (calculated for responders only) was defined as time from the initial documented response (partial response or better) to confirmed disease progression, based on IMWG criteria.

Time frame:
From first dose until the data cut-off date of 03 September 2014; maximum time for follow-up was 36 weeks

No measurements were reported for this outcome.

SecondaryKaplan-Meier Estimates of Duration of Response (Later Cut-off Date)

Duration of response (calculated for responders only) was defined as time from the initial documented response (partial response or better) to confirmed disease progression, based on IMWG criteria.

Time frame:
From the first dose until the final data cut-off date of 25 September 2015; maximum duration on treatment was 80.9 weeks
Reported as:
Median · weeks
Kaplan-Meier Estimates of Duration of Response (Later Cut-off Date)
weeksPomalidomide Plus Dexamethasone
Kaplan-Meier Estimates of Duration of Response (Later Cut-off Date)NA (20.100 to NA)
SecondaryKaplan-Meier Estimates of Progression-free Survival (PFS)

PFS was calculated as the time from the first dosing to the first documented progressive disease, as determined by the investigators based on the IMWG Uniform Response criteria, or death, whichever occurred earlier

Time frame:
From the first dose until the data cut-off date of 03 September 2014; maximum time on treatment was 36.0 weeks
Reported as:
Median · weeks
Kaplan-Meier Estimates of Progression-free Survival (PFS)
weeksPomalidomide Plus Dexamethasone
Kaplan-Meier Estimates of Progression-free Survival (PFS)19.0 (8.100 to NA)
SecondaryKaplan-Meier Estimates of PFS (Later Cut-off Date)

PFS was calculated as the time from the first dosing to the first documented progressive disease, as determined by the investigators based on the IMWG Uniform Response criteria, or death, whichever occurred earlier

Time frame:
From the first dose until the final data cut-off date of 25 September 2015; maximum duration on treatment was 80.9 weeks
Reported as:
Median · weeks
Kaplan-Meier Estimates of PFS (Later Cut-off Date)
weeksPomalidomide Plus Dexamethasone
Kaplan-Meier Estimates of PFS (Later Cut-off Date)32.10 (9.700 to NA)
SecondaryNumber of Participants With Adverse Events

Relation to study drug was assessed by the Investigator as either suspected or not suspected. Counts represent the suspected relationship. Severity was assessed using National Cancer Institute Common Toxicity Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0): 1= Mild 2= Moderate 3= Severe 4= Life-threatening and 5= Death related to AE. Serious AEs (SAEs) were those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above. Treatment Emergent Adverse Event (TEAE) was defined as any AE occurring on or after the first treatment of the study medication and within 28 days after the last dose.

Time frame:
From first dose of study drug to final data cut-off date of 25 Sept 2015, maximum duration on treatment was 80.9 weeks
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsPomalidomide Plus Dexamethasone
Any 1 TEAE36
TEAE related to any study drugs33
TEAE related to Pomalidomide33
TEAE related to Dexamethasone(Dex)27
TEAE with ≥ Grade (GR) 333
≥ 1TEAE ≥ GR 3 related to any study drug30
TEAE ≥ GR 3 related to Pomalidomide30
TEAE ≥ GR 3 related to Dexamethasone11
≥ 1 serious TEAE16
Serious TEAE related to any study drug8
Serious TEAE related to Pomalidomide8
Serious TEAE related to Dexamethasone6
TEAE leading to stopping of any study drug5
TEAE leading to discontinuation of Pomalidomide5
TEAE leading to discontinuation of Dexamethasone5
Related TEAE leading to stopping of study drug4
Related TEAE leading to stopping of Pomalidomide4
Related TEAE leading to stopping Dexamethasone4
TEAE leading to dose reduction of any study drug19
TEAE leading to dose reduction of Pomalidomide10
TEAE leading to dose reduction of Dexamethasone15
TEA leading to dose interruption of any study drug20
TEAE leading to dose interruption of Pomalidomide18
TEAE leading to dose interruption of Dexamethasone11
Related TEAE leading to dose reduction of any drug18
Related TEAE causing a dose reduction Pomalidomide10
≥1 related TEAE causing a dose reduction: Dex14
Related TEAE leading to interruption of drugs16
Related TEAE causing an interruption Pomalidomide15
Related TEAE causing an interruption to Dex8
TEAE Grade 53

Adverse events

Collected over From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pomalidomide Plus Dexamethasone—16/36 (44.4%)36/36 (100%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventPomalidomide Plus Dexamethasone
ANAEMIABlood and lymphatic system disorders5/36
PNEUMONIAInfections and infestations5/36
NEUTROPENIABlood and lymphatic system disorders2/36
ASTHMARespiratory, thoracic and mediastinal disorders2/36
CANCER PAINNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/36
CONSTIPATIONGastrointestinal disorders2/36
THROMBOCYTOPENIABlood and lymphatic system disorders1/36
PNEUMONIA PNEUMOCOCCALInfections and infestations1/36
CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders1/36
HYPOXIARespiratory, thoracic and mediastinal disorders1/36
Most frequent other events
Showing 10 of 65
Most frequent other events
EventPomalidomide Plus Dexamethasone
NEUTROPENIABlood and lymphatic system disorders26/36
ANAEMIABlood and lymphatic system disorders17/36
THROMBOCYTOPENIABlood and lymphatic system disorders16/36
PYREXIAGeneral disorders9/36
CONSTIPATIONGastrointestinal disorders9/36
NASOPHARYNGITISInfections and infestations9/36
LYMPHOPENIABlood and lymphatic system disorders8/36
OEDEMA PERIPHERALGeneral disorders7/36
DIARRHOEAGastrointestinal disorders7/36
NAUSEAGastrointestinal disorders7/36

Baseline characteristics

Safety Population included all participants who received at least one dose of study medication

Age, Continuous
Age, Continuous(years)Pomalidomide Plus Dexamethasone
Median64.5 (43 to 78)
Age, Customized
Age, Customized(participants)Pomalidomide Plus Dexamethasone
≤ 75 Years Old32
> 75 Years Old4
Sex: Female, Male
Sex: Female, Male(Participants)Pomalidomide Plus Dexamethasone
Female20
Male16
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pomalidomide Plus Dexamethasone
American Indian or Alaska Native0
Asian36
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Time from first diagnosis
Time from first diagnosis(years)Pomalidomide Plus Dexamethasone
Median4.65 (0.6 to 21.1)
Durie-Salmon Multiple myeloma staging at screening
Durie-Salmon Multiple myeloma staging at screening(participants)Pomalidomide Plus Dexamethasone
Stage I7
Stage II16
Stage III13
Eastern Cooperative Oncology Group Performance Status] (ECOG)
Eastern Cooperative Oncology Group Performance Status] (ECOG)(participants)Pomalidomide Plus Dexamethasone
0 = (Asymptomatic)17
1 = (Symptomatic but completely ambulatory)16
2 = (Ambulatory but unable to work)3
3 = (Limited self-care)0
4 = (Completely disabled)0
Prior Chemotherapy Regimens
Prior Chemotherapy Regimens(regimens)Pomalidomide Plus Dexamethasone
Median6.0 (2 to 14)

2 further baseline measures are reported on the registry.

08

Study locations

14 sites
  • Celgene Trial Site
    Nagoya, Aichi 467-8602, Japan
  • Celgene Trial Site
    Kamogawa, Chiba 298-8602, Japan
  • Celgene Trial Site
    Mito, Ibaragi 311-3193, Japan
  • Celgene Trial Site
    Isehara, Kanagawa 259-1193, Japan
  • Celgene Trial Site
    Fukuoka, 812-8582, Japan
  • Celgene Trial Site
    Hiroshima, 734-8551, Japan
  • Celgene Trial Site
    Kyoto, 602-8566, Japan
  • Celgene Trial Site
    Niigata, 951-8566, Japan
  • Celgene Trial Site
    Okayama, 701-1192, Japan
  • Celgene Trial Site
    Osaka, 543-8555, Japan
  • Celgene Trial Site
    Tokyo, 104-0045, Japan
  • Celgene Trial Site
    Tokyo, 150-8935, Japan
  • Celgene Trial Site
    Tokyo, 160-8582, Japan
  • Celgene Trial Site
    Tokyo, 162-8655, Japan
09

References and documents

Publications

  • Ichinohe T, Kuroda Y, Okamoto S, Matsue K, Iida S, Sunami K, Komeno T, Suzuki K, Ando K, Taniwaki M, Tobinai K, Chou T, Kaneko H, Iwasaki H, Uemura C, Tamakoshi H, Zaki MH, Doerr T, Hagiwara S. A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial. Exp Hematol Oncol. 2016 Apr 18;5:11. doi: 10.1186/s40164-016-0040-7. eCollection 2015. PubMed 27096106 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Sep 2014 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2013
First posted
Dec 13, 2013
Start
Dec 2013
Primary completionActual
Sep 2014
CompletionActual
Sep 2015
Results first posted
Nov 10, 2015
Last update
Nov 1, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02011113
Responsible party
Sponsor
First posted
Dec 13, 2013
Start date
Dec 2013
Primary completion
Sep 2014
Completion
Sep 2015
Results posted
Nov 10, 2015
Last update
Nov 1, 2016

Study contacts

Toru Sasaki, Director
study director · Celgene K.K.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pomalidomide · Dexamethasone

Start the discussion